BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021;151:30-8. [PMID: 33285469 DOI: 10.1016/j.lungcan.2020.11.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol 2023;18:181-93. [PMID: 36307040 DOI: 10.1016/j.jtho.2022.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Sakagami M, Inokuchi H, Mukumoto N, Itoyama H, Hamaura N, Yamagishi M, Mukumoto N, Matsuda S, Shibuya K. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.. [DOI: 10.21203/rs.3.rs-1974420/v1] [Reference Citation Analysis]
3 Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sánchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol 2022:S1556-0864(22)01500-3. [PMID: 35961520 DOI: 10.1016/j.jtho.2022.07.1148] [Reference Citation Analysis]
4 Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol 2022;11:44. [PMID: 35907881 DOI: 10.1186/s40164-022-00297-8] [Reference Citation Analysis]
5 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
6 Remon J, Levy A, Singh P, Hendriks LEL, Aldea M, Arrieta O. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial? Ther Adv Med Oncol 2022;14:17588359221113268. [PMID: 35923929 DOI: 10.1177/17588359221113268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guberina M, Guberina N, Pöttgen C, Gauler T, Richlitzki C, Metzenmacher M, Wiesweg M, Plönes T, Forsting M, Wetter A, Herrmann K, Hautzel H, Darwiche K, Theegarten D, Aigner C, Schuler M, Stuschke M, Eberhardt WE. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy 2022. [PMID: 35822656 DOI: 10.2217/imt-2021-0341] [Reference Citation Analysis]
8 Raez LE, Arrieta O, Chamorro DF, Soberanis-piña PD, Corrales L, Martín C, Cuello M, Samtani S, Recondo G, Mas L, Zatarain-barrón ZL, Ruíz-patiño A, García-robledo JE, Ordoñez-reyes C, Jaller E, Dickson F, Rojas L, Rolfo C, Rosell R, Cardona AF. Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). Front Oncol 2022;12:904800. [DOI: 10.3389/fonc.2022.904800] [Reference Citation Analysis]
9 Fournel P, Bareille Saint-gaudens A. Apport de l’immunothérapie dans les stades non métastatiques et non résécables. Revue des Maladies Respiratoires Actualités 2022;14:1S40-1S46. [DOI: 10.1016/s1877-1203(22)00012-x] [Reference Citation Analysis]
10 Yin T, Wang P, Yu J, Teng F. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma. Int Immunopharmacol 2022;106:108623. [PMID: 35203044 DOI: 10.1016/j.intimp.2022.108623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;:JCO2101308. [PMID: 35108059 DOI: 10.1200/JCO.21.01308] [Cited by in Crossref: 54] [Cited by in F6Publishing: 73] [Article Influence: 54.0] [Reference Citation Analysis]
12 Kaen DL, Minatta N, Russo A, Malapelle U, de Miguel-Pérez D, Rolfo C. Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? Adv Exp Med Biol 2021;1342:113-42. [PMID: 34972964 DOI: 10.1007/978-3-030-79308-1_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Miyasaka Y, Sato H, Okano N, Kubo N, Kawamura H, Ohno T. A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy. Cancers (Basel) 2021;14:203. [PMID: 35008367 DOI: 10.3390/cancers14010203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Yang Y, Zhang T, Zhou Z, Liang J, Chen D, Feng Q, Xiao Z, Hui Z, Lv J, Deng L, Wang X, Wang W, Wang J, Liu W, Zhai Y, Wang J, Bi N, Wang L. Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Thorac Cancer 2021. [PMID: 34927371 DOI: 10.1111/1759-7714.14218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Vrankar M, Stanic K, Jelercic S, Ciric E, Vodusek AL, But-Hadzic J. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience. Radiol Oncol 2021;55:482-90. [PMID: 34821136 DOI: 10.2478/raon-2021-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kraus KM, Fischer JC, Borm KJ, Vogel MME, Pigorsch SU, Devečka M, Combs SE. Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. Sci Rep 2021;11:7624. [PMID: 33828117 DOI: 10.1038/s41598-021-86863-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]